<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9720">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05691699</url>
  </required_header>
  <id_info>
    <org_study_id>M24-112</org_study_id>
    <nct_id>NCT05691699</nct_id>
  </id_info>
  <brief_title>A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults</brief_title>
  <official_title>A Phase 1 First in Human, Single and Multiple Ascending Dose and Food Effect and Drug-Drug Interaction in Healthy Subjects to Evaluate the Safety, Tolerability and Assessment of Pharmacokinetics of ABBV-903</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate adverse events and tolerability of single and&#xD;
      multiple doses of ABBV-903, and to assess how the drug moves through the body in healthy&#xD;
      adult volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2023</start_date>
  <completion_date type="Anticipated">September 18, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 18, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Baseline to Day 36</time_frame>
    <description>Cmax will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>Baseline to Day 36</time_frame>
    <description>Tmax will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Phase Elimination Constant (β)</measure>
    <time_frame>Baseline to Day 36</time_frame>
    <description>Apparent terminal phase elimination constant (β) will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Phase Elimination Half-life (t1/2)</measure>
    <time_frame>Baseline to Day 36</time_frame>
    <description>Terminal phase elimination half-life (t1/2) will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve (AUC)</measure>
    <time_frame>Baseline to Day 36</time_frame>
    <description>AUC will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve from Time 0 Until the Last Measurable Concentration (AUCt)</measure>
    <time_frame>Baseline to Day 36</time_frame>
    <description>AUCt will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve from Time 0 Until Infinity (AUCinf)</measure>
    <time_frame>Baseline to Day 36</time_frame>
    <description>AUCinf will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Baseline to Day 66</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Part 1, ABBV-903</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single ascending dose of ABBV-903 in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single ascending dose of placebo in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, ABBV-903</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple ascending doses of ABBV-903 in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple ascending doses of placebo in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3, Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Part 3 will follow Sequence 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3, Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Part 3 will follow Sequence 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-903</intervention_name>
    <description>Capsule; oral</description>
    <arm_group_label>Part 1, ABBV-903</arm_group_label>
    <arm_group_label>Part 2, ABBV-903</arm_group_label>
    <arm_group_label>Part 3, Sequence 1</arm_group_label>
    <arm_group_label>Part 3, Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for ABBV-903</intervention_name>
    <description>Capsule; oral</description>
    <arm_group_label>Part 1, Placebo</arm_group_label>
    <arm_group_label>Part 2, Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Capsule; oral</description>
    <arm_group_label>Part 3, Sequence 1</arm_group_label>
    <arm_group_label>Part 3, Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) is =&gt; 18.0 to &lt;= 32 kg/m2 after rounded to the nearest tenth, at&#xD;
             Screening and upon initial confinement.&#xD;
&#xD;
          -  A condition of general good health, based upon the results of a medical history,&#xD;
             physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram&#xD;
             (ECG).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any clinically significant illness/infection/major febrile illness,&#xD;
             hospitalization, or any surgical procedure within 30 days prior to the first dose of&#xD;
             study drug.&#xD;
&#xD;
          -  History of epilepsy, any clinically significant cardiac, respiratory (except mild&#xD;
             asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric&#xD;
             disease or disorder, or any uncontrolled medical illness.&#xD;
&#xD;
          -  Evidence of dysplasia or history of malignancy (including lymphoma and leukemia) other&#xD;
             than successfully treated non-metastatic cutaneous squamous cell, basal cell carcinoma&#xD;
             or localized carcinoma in situ of the cervix.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Acpru /Id# 251279</name>
      <address>
        <city>Grayslake</city>
        <state>Illinois</state>
        <zip>60030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.abbvieclinicaltrials.com/study/?id=M24-112</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2023</verification_date>
  <study_first_submitted>January 9, 2023</study_first_submitted>
  <study_first_submitted_qc>January 18, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2023</study_first_posted>
  <last_update_submitted>June 6, 2023</last_update_submitted>
  <last_update_submitted_qc>June 6, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ABBV-903</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

